Corrado Tamburino, MD, PhD

Similar documents
Paravalvular Regurgitation is a Risk Factor Following TAVI

e Corrado Tamburino, MD, PhD

Complications after TAVI: VARC Definitions, Frequency and Management Considerations Patrick W. Serruys, Nicolo Piazza,

ΔΙΑΔΕΡΜΙΚΗ ΑΝΣΙΚΑΣΑΣΑΗ ΑΟΡΣΙΚΗ ΒΑΛΒΙΔΑ αντιμετώπιση επιπλοκών ΠΕΣΡΟ. ΔΑΡΔΑ, MD, FESC IICE 2012

Comments restricted to Sapien and Corevalve 9/12/2016. Disclosures: Core Lab contracts with Edwards Lifesciences, Middlepeak, Medtronic

TAVI Technology and Procedural Changes

Optimal Imaging Technique Prior to TAVI -Echocardiography-

Incidence and Management of Early Implant Failure after Transcatheter Aortic Valve Implantation

Paris, August 28 th Gian Paolo Ussia on behalf of the CoreValve Italian Registry Investigators

Imaging in TAVI. Jeroen J Bax Dept of Cardiology Leiden Univ Medical Center The Netherlands Davos, feb 2013

SAPIEN 3 Sizing Considerations:

New imaging modalities for assessment of TAVI procedure and results. R Dulgheru, MD Heart Valve Clinic CHU, Liege

Transcatheter Aortic Valve Replacement

Andrzej Ochala, MD Medical University of Silesia, Katowice, Poland

Mild paravalvular regurgitation is not an independent predictor of mortality following TAVI

Aortic valve implantation using the femoral and apical access: a single center experience.

How Do I Evaluate a Patient Being Considered for TAVR? Sunday, February 14, :00 11:25 PM 25 min

Transcatheter Aortic Valve Implantation. SSVQ November 23, 2012 Centre Mont-Royal 15:40

Prosthesis-Patient Mismatch in High Risk Patients with Severe Aortic Stenosis in a Randomized Trial of a Self-Expanding Prosthesis

Evolut R in bicuspid valve anatomies

TAVR-Update Andrzej Boguszewski MD, FACC, FSCAI Vice Chairman, Cardiology Mid-Michigan Health Associate Professor Michigan State University, Central

Jonathon Leipsic MD FRCPC FSCCT. Vice Chairman of Radiology University of British Columbia. Disclosures

Percutaneous Treatment of Valvular Heart Diseases: Lessons and Perspectives. Bernard Iung Bichat Hospital, Paris

Le TAVI pour tout le monde?

The Role of Imaging in Transcatheter Aortic Valve Implantation

Severity of AS Degree of AV calcification (? Bicuspid AV), annulus size, & aortic root

PARAVALVULAR LEAK POST TAVR. Elements of Follow-up Post TAVR

Echo Assessment Pre-TAVI

For Personal Use. Copyright HMP 2013

CoreValve in a Degenerative Surgical Valve

CIPG Transcatheter Aortic Valve Replacement- When Is Less, More?

Aortic valve calcium load before TAVI: Is it important?

TAVR: Echo Measurements Pre, Post And Intra Procedure

Transcatheter Aortic Valve Replacement: Current and Future Devices: How do They Work, Eligibility, Review of Data

PVL Assessment. Is paravalvular regurgitation after TAVR still an important consideration in 2018?

A review of the complications associated with Transcatheter Aortic Valve Implantation.

Transcatheter Aortic Valve Implantation (TAVI) - 5 important lessons learnt from HK experiences Michael KY Lee

Minimalist Transcatheter Aortic Valve Replacement (MA-TAVR)

Federico M Asch MD, FASE MedStar Heart and Vascular Institute Georgetown University Washington, DC

Complicanze durante TAVI. Brambilla Nedy IRCCS Policlinico San Donato

Critical role of multi-modality planning in Transcatheter Mitral Valve Replacement

Valve Disease in Patients With Heart Failure TAVI or Surgery? Miguel Sousa Uva Hospital Cruz Vermelha Lisbon, Portugal

RANDOMISED TRIALS TAVI WITH SAVR STEPHAN WINDECKER AORTIC VALVE DISEASE COMPARING

Image Assistance in TAVI Why CT? Won-Jang Kim, MD, PhD Clinical Assistant Professor of Medicine, Heart Institute, Asan Medical Center, Seoul, Korea

Transcatheter aortic valve implantation and pre-procedural risk assesment

TAVI in Korea, How to Avoid Conduction

TAVI- Is Stroke Risk the Achilles Heel of Percutaneous Aortic Valve Repair?

Results of Transfemoral Transcatheter Aortic Valve Implantation

Is TAVI ready for prime time in: - Intermediate risk patients? - Low risk patients?

TAVR for Valve-In-Valve. Brian O Neill Assistant Professor of Medicine Department of Medicine, Section of Cardiology

Indication, Timing, Assessment and Update on TAVI

Incorporating the intermediate risk in Transcatheter Aortic Valve Implantation (TAVI)

Prof. Dr. Thomas Walther. TAVI in ascending aorta / aortic root dilatation

Incidence and Treatment for LM In-Stent

2/10/2012. The Role of Multimodality Imaging in Percutaneous Valve Interventions. This is truly a TEAM work. Overview. Overview

DISCLOSURE. Relevant Financial Relationship(s) Off Label Usage. None. None

TAVR 2018: TAVR has high clinical efficacy according to baseline patient risk! ii. Con

PARTNER 2A & SAPIEN 3: TAVI for intermediate risk patients

Percutaneous Therapy for Calcific Mitral Valve Disease

Outcome of Next-Generation Transcatheter Valves in Small Aortic Annuli: A Multicenter Propensity-Matched Comparison

I will not discuss off label use or investigational use in my presentation.

Edwards Sapien. Medtronic CoreValve. Inoperable FDA approved High risk: in trials. FDA approved

First Transfemoral Aortic Valve Implantation In Bulgaria - Crossing The Valve With The Device Is Not Always

Is TAVR the treatment of choice for high risk diabetic patients with aortic stenosis? Insights from the FRANCE2 Registry

Successful Transfemoral Edwards Sapien Aortic. Valve Implantation in a Patient with Previous. Mitral Valve Replacement

History. 2D echo before TAVI. 88 female Hypertensive - hyperlipidemic History of LOC syncope Echo: severe AS AV gradient 90 mmhg Good LV LVH

New Cardiovascular Devices and Interventions: Non-Contrast MRI for TAVR Abhishek Chaturvedi Assistant Professor. Cardiothoracic Radiology

SYNTAX score before decision making! Corrado Tamburino, MD, PhD

Debate: SAVR for Low-Risk Patients in 2017 is Obsolete AVR vs TAVI

After PARTNER 2A/S3i and SURTAVI: What is the Role of Surgery in Intermediate-Risk AS Patients?

TAVR Cases. Disclosures 2/17/2018. February 17, :15 3:30 PM 15 min

TAVR for Complex Aortic Valvular Conditions

Current Evidence in TAVI patients using ACURATE and LOTUS valves

How to Avoid Prosthesis-Patient Mismatch

DICE Session. The endocarditis team. Bernard Iung Bichat Hospital, Paris Diderot University Paris, France

Aortic Stenosis and TAVR TARUN NAGRANI, MD INTERVENTIONAL AND ENDOVASCULAR CARDIOLOGIST, SOMC

Peri-operative results and complications in 15,964 transcatheter aortic valve implantations from the German Aortic valve RegistrY (GARY)

TAVR today: High Risk, Intermediate Risk Population, and Valve in Valve Therapy

CASE PRESENTATION CASE REPORT

TAVR for low-risk patients in 2017: not so fast.

Transcatheter Valve-In-Valve Implantation for Failed Balloon-Expandable Transcatheter Aortic Valves

TAVI: The Real Deal? Marc Pelletier, MD Head, Department of Cardiac Surgery New Brunswick Heart Centre

HOW IMPORTANT ARE THESE ECHO MEASUREMENTS ANYWAY?

Aortic stenosis (AS) remains the most common

7 th Conference of Transcatheter Heart Valve Therapies

Post-TAVI Cerebral Embolisms and Potential Protection Means

3D Printing & Echocardiography

TAVR IN INTERMEDIATE-RISK PATIENTS

This article appeared in a journal published by Elsevier. The attached copy is furnished to the author for internal non-commercial research and

Transcatheter Aortic Valve Implantation (TAVI)

Pacemaker After Transcatheter Aortic Valve Implantation: Where, When and How?

Prevention and Management of Vascular Complications Related to Transcatheter Aortic Valve Implantation

TAVI: Transapical Procedures

Low Gradient Severe AS: Who Qualifies for TAVR? Andrzej Boguszewski MD, FACC, FSCAI Vice Chairman, Cardiology Mid-Michigan Health Associate Professor

Aortic Stenosis: Open vs TAVR vs Nothing

ECHO HAWAII. Role of Stress Echo in Valvular Heart Disease. Not only ischemia! Cardiomyopathy. Prosthetic Valve. Diastolic Dysfunction

PERCUTANEOUS STRUCTURAL UPDATES TAVR WATCHMAN(LEFT ATRIAL APPENDAGE OCCLUDERS) MITRACLIP PARAVALVULAR LEAK REPAIRS ASD/PFO CLOSURES VALVULOPLASTIES

The Future of Medicine. Who to TAVR? Azeem Latib MD EMO-GVM Centro Cuore Columbus and San Raffaele Scientific Institute, Milan, Italy

Impact of CoreValve size selection based on multi-slice computed tomography on paravalvular leak after transcatheter aortic valve implantation

Journal of the American College of Cardiology Vol. 59, No. 14, by the American College of Cardiology Foundation ISSN /$36.

Transcription:

Paravalvular leak: acceptable or not Corrado Tamburino, MD, PhD Full Professor of Cardiology, Director of Postgraduate School of Cardiology Chief Cardiovascular Department, Director Cardiology Division, Interventional Cardiology and Heart Failure Unit, University of Catania, Ferrarotto Hospital, Catania, Italy

Disclosure Statement of Financial Interest I, Corrado Tamburino, DO NOT have a financial interest/arrangement or affiliation with one or more organizations that could be perceived as a real or apparent conflict of interest in the context of the subject of this presentation

Just a cosmetic issue?

What we have learnt Very common finding after TAVI Usually trivial or mild Multimodal degree quantification Long-term impact

Roadmap of the lecture What is the incidence? Is it associated with worse outcomes? Is it predictable? How to manage it?

Incidence, ES & CRS 100 70-90% 80 60 40 20 0 10-30% 10-30% No PVL Any PVL Grade 2 PVL Rajan et al. Catheter Cardiovasc Interv 2009 Clavel et al. J Am Coll Cardiol 2009 Jilaihawi et al. Eur Heat J 2009 Himbert et al. J Am Coll Cardiol 2008 Moss et al. JACC Cardiovasc asc Imag 2008 Detaint t et al. JACC Cardiovasc asc Interv 2009

Incidence, Edwards-SAPIEN European PARTNER 47.0% REVIVAL SOURCE 1.9% 22.9% 18.7% 58.4% PARTNER cohort A 12.2% PARTNER cohort B 11.8% 42.0% 46.0% 0% 20% 40% 60% moderate < moderate No

Incidence, CoreValve Nuis et al. 13.0% Takagi et al. 20.3% 26.6% 53.1% Buellesfeld et al. 6.0% 42.0% 52.0% Tamburino et al. 21.0% 0% 20% 40% 60% moderate < moderate No

Incidence, ES & CRS Eltchaninoff et al. 9.5% Zahn et al. 17.5% 27.6% 54.9% German Registry 17.2% 27.7% 55.1% UK Registry 13.6% 39.0% 47.4% 0% 20% 40% 60% moderate < moderate No

Impact on outcomes Tamburino et al. Circulation 2011

Impact on outcomes nts) PPL at 1 year (% of actua arial numb er of patie 100% 80% 60% 40% 20% 0% N=661-20% PV 0+ PV 1+ PV 2+ PV 3+ PV 4+ Post-procedural aortic regurgitation grade AR none AR 1+ AR 2+ AR 3+ AR 4+ Same or better worse Tamburino et al. Circulation 2011

Impact on outcomes Overall mortality Hazard ratio 95% LCL 95% UCL p value Intraprocedural stroke 15.76 3.27 75.90 0.001 Pre-procedural mitral regurgitation 3+ or 4+ 4.62 1.66 12.87 0.003 Systolic pulmonary artery pressure > 60 mmhg 3.21 1.19 8.71 0.02 Prior acute pulmonary edema 2.75 1.32 5.72 0.007 Diabetes mellitus 2.45 1.19 5.07 0.02 Early mortality Odds ratio 95% LCL 95% UCL p value Conversion to open heart surgery 38.68 286 2.86 522.5959 0.006006 Cardiac tamponade 10.97 1.59 75.61 0.02 Major access site complications 8.47 1.67 42.82 0.01 Left ventricular ejection fraction < 40% 3.51 1.62 7.62 0.002 Prior balloon aortic valvuloplasty 2.87 1.24 6.65 0.01 Diabetes mellitus 2.66 1.26 5.65 0.01 Late mortality Hazard ratio 95% LCL 95% UCL p value Prior stroke 5.468 1.47 20.39 0.01 Post-procedural paravalvular leak 2+ 3.785 1.57 9.10 0.003 Prior acute pulmonary edema 2.696 1.09 6.68 0.03 Chronic kidney disease 2.532 1.01 6.35 0.048 Tamburino et al. Circulation 2011

Impact on outcomes AR index=[(dbp -LVEDP)/SBP] x100 146 consecutive TAVI with Medtronic CoreValve PVL assessed by Echo, angio, and measurement of the AR index Patients with AR index <25 had a significantly increased 1-year mortality risk compared with patients with AR index 25 Sinning et al., J Am Coll Cardiol 2012

Impact on outcomes AR index <25 AR index >25 Mo ortality (%) 100 79,8% 75 None/mild periar 50 25 0 p (log rank-test) < 0,001 Hazard Ratio (95% CI) = 3,89 (2,02-7,49) 36,4% Moderate/severe periar 0 120 240 360 Time (days) Mortality (%) 100 75 50 25 0 p (log rank-test) < 0,001 Hazard Ratio (95% CI) = 2,97 (1,57-5,63) 83,3% None/mild periar 54,0% Moderate/severe periar 0 120 240 360 Time (days) Sinning et al., J Am Coll Cardiol 2012

Kodali et al., NEJM 2012

Is it predictable? Annulus measurement Calcium burden evaluation Operator experience MSCT is mandatory!!!

Aortic root anatomy not so simple! Piazza N, Circ Cardiovasc Interv 2008;1:74-8181

Aortic root anatomy and lot of calcium!

Heavy calcifications prosthesis underexpansion

Is it predictable? Détaint et al. JACC Cardiovasc Interv 2009

Is it predictable? Détaint et al. JACC Cardiovasc Interv 2009

Is it predictable? MDCT mean diameter (0.81, 95%CI: 0.68-0.88), MDCT area (0.80, 95%CI: 0.65-0.90), TEE diameter (0.70, 95%CI: 0.51-0.88). 0 Willson et al. J Am Coll Cardiol 2012

Is it predictable? Undersized prosthesis 4,5 Annulus size 3,5 4,5 p Operator Experience 1,4 Calcification 2,3,6 PVL Cover index 4 1 Detaint et al. JACC Interv 2009 2 Coli et al. Circulation 2009 4 Willson et al. J Am Coll Cardiol 2012 5 Takagi et al. Catheter Cardiovasc Interv 2011 3 Delgado et al. Circulation 2009 6 John et al. JACC Cardiovasc asc Interv 2010 0

How to prevent it? 1. Accurate aortic root assessment MSCT has to be the preferred tool 2. Oversize the device Pay attention to damage on the aortic root

How to prevent it? Babaliaros et al. JACC Cardiovasc Interv 2011

How to manage it? No doubt...it has to be treated!

How to manage it? 1. Post-dilatation... dilatation...crs & ES 2. Snaring...CRS 3. Valve-in-Valve... Valve...CRS & ES 4. Anchoring balloon...es

How to manage it? Para-valvular Leak Frame Postdilatation underexpansion lower deployment with Snaring Valve-in in-valve Technique e respect to the annulus undersized device with Postdilatation or ViV is respect to the aortic futile annulus higher deployment with Valve-in in-valve respect to the annulus

Conclusions Mild PVL complicates the majority of TAVI procedures Accurate aortic root evaluation is mandatory (MSCT) Prefer oversize prosthesis but be careful! Work now should be directed toward reducing PVL with improved device designs, techniques for more precise valve sizing and positioning, and judicious use of post- TAVI dilation